Exosla Therapeutics
Biotechnology Research
The Key Challenges in Manufacturing Msc-sev Products
2 employees
- Employees
- 2
Exosla Therapeutics Overview
- Headquarters
- The Key Challenges in Manufacturing Msc-sev Products
- Website
- www.exosla.com
- Industry
- Biotechnology Research
- Employees
- 2
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
About Exosla Therapeutics
Exosla Therapeutics is a UK/German pre-clinical biotech company focused on immune-related diseases, including neuroinflammation. It offers a safe and scalable immunotherapy by leveraging the multimodal action of high-performing extracellular vesicles (EVs) from specific monoclonal mesenchymal stem/stromal cell (MSC) lines, which were previously immortalised to supply the full drug life cycle. The scientific and translational efforts are built on over a decade of foundational work by Prof. Bernd Giebel at the University of Duisburg-Essen, a pioneer in the MSC-EV field.
Exosla Therapeutics Contact Details
- People in AeroLeads
- 1
Exosla Therapeutics Org Chart
Sample employees and titles| Name | Title | Location | Contact |
|---|---|---|---|
| Pierre Arsène | Founder & CEO @ Mursla Bio - Unlocking Organ-specific Biology in Blood to Transform Ai-enabled Precision Medicine and Diagnostics |
View
|
Compare Similar Companies to Exosla Therapeutics
Amphista Therapeutics Limited
Biotechnology Research
Maxion Therapeutics
Biotechnology
analyze & realize GmbH
Research Services
Glycostem Therapeutics
Biotechnology
StemSight
Biotechnology Research
Mursla Bio
Biotechnology Research
Crowlight Partners
Business Consulting And Services
MicroA
Biotechnology Research
Aspire Biosciences
Biotechnology Research
German Society for Extracellular Vesicles
Research Services